Choosing a Clinical Trial Management System: Sandbox-Test It Against Your Own Standard Operating Procedures Before You Switch

Every site owner has lived some version of this story. The demo was polished. The price was right. Six months after go-live, your coordinators are keeping shadow spreadsheets because the system you bought does not match how your site actually works — and switching again would cost more than staying miserable.

A clinical trial management system (CTMS) sits underneath almost everything a research site does: visit scheduling, subject tracking, invoicing, budget management, and reporting. Choosing the wrong one is a multi-year tax on every study you run. The fix is not a longer demo. It is a sandbox trial: a structured test of the system, run on your own standard operating procedures (SOPs), before you sign.

Why Vendor Demonstrations Mislead

A demonstration is a performance, and it is performed on the vendor's terms:

• Scripted workflows. The presenter follows the path the software handles best. Your site runs on exceptions — rescheduled visits, screen failures, protocol deviations, unscheduled visits at 4:30 on a Friday afternoon.
• The vendor's data. Demo databases are clean, small, and tidy. Your real data includes years of closed studies, messy budgets, and subjects with the same last name.
• The vendor's pace. A trained presenter clicks through in seconds what takes your newest coordinator ten minutes to find. A system that looks intuitive in a demo can be a daily friction point for the people who live in it.

A demo answers the vendor's questions, not yours. Your SOPs define how work is supposed to happen at your site. If the system cannot execute your SOPs, the system is wrong for your site, no matter how well it demos.

How to Run a Sandbox Trial

Ask the vendor for a sandbox (a test environment) with full functionality, and treat the evaluation like a small study startup. In our experience, two to three weeks of structured testing beats six months of regret.

Build two test studies from your own SOPs. Take one simple protocol — a straightforward visit schedule, few procedures — and one complex protocol with the features that strain a system: multiple arms or cohorts, unscheduled-visit windows, screening and rescreening rules, and pass-through costs. Use fictional subjects; never load real patient identifiers into a vendor sandbox.

Load real operational load. Enter the actual visit schedules, with real visit windows and tolerances. Run the scenarios your SOPs describe for the hard days: a screen failure and its documentation, an unscheduled visit, a subject withdrawal, a visit completed out of window.

Run the money end to end. Build the study budget the way your finance team builds it, generate invoices from completed visits, apply a holdback or partial payment, and reconcile. In our experience, budget and invoicing gaps are the most common reason sites end up maintaining parallel spreadsheets — and they are the easiest gaps to expose in a sandbox.

Put your own people on it. The coordinators, regulatory staff, and finance staff who will use the system daily should run the scenarios, not watch a manager do it. Note every point where the system forces a workaround — that list is your real evaluation.

What to Test Specifically

• Source-data priority. Source documentation is the record an inspector reads. FDA's compliance program for inspections of clinical investigators (Compliance Program 7348.811) directs inspectors to compare the original source records with the case report forms, and investigators are required to keep adequate and accurate case histories (21 CFR 312.62(b) for drug studies, 21 CFR 812.140(a)(3) for device studies). So ask: does the system organize work around source documents — visit by visit, procedure by procedure — or does it treat source as an afterthought bolted onto a scheduling tool? A system that fights your source workflow will fight your staff on every visit. At Amavita Research Services, the Miami cardiovascular research site where I serve as CEO, we work by a simple rule: whatever makes clean source documentation harder will eventually surface in a monitoring visit or an audit. Test for it first.
• Integrations. Your CTMS does not live alone. Test the actual connections to your recruitment tools, your electronic data capture (EDC) system, and your electronic health record, if you use one. "Integration available" can mean a live two-way interface, a nightly file export, or a manual download someone must remember to run. Verify which one you are getting, with your own test data. FDA's 2024 guidance on electronic systems in clinical investigations expects validation to cover data transfers and interfaces between systems, and notes that the organization deploying a vendor's system may review the vendor's validation documentation to judge whether the system is fit for purpose. Ask for that documentation during the sandbox, not after go-live.
• The artificial intelligence (AI) roadmap. Most vendors now present one. Ask what AI features are shipped and in production at other sites today, what is in beta, and what is a slide. Then test only what is shipped. A roadmap is a promise; price and evaluate the product that exists.
• Finance reporting. Your finance team needs specific reports: receivables aging by sponsor, earned-versus-invoiced by study, pass-through tracking, month-end close support. Hand the vendor your actual report list and have them produce each one from your test data. If a report requires a custom build, get the cost and timeline in writing before you sign.

The Switching Costs a Sandbox Surfaces Early

Once a CTMS is embedded, leaving it is expensive in ways that never appear on a quote: migrating years of study and subject data (and deciding what historical data you will lose), retraining every role, rewriting the SOPs that referenced the old system, and the productivity dip during transition. A sandbox trial surfaces these costs while they are still hypothetical. If your test studies are painful to build, imagine migrating forty real ones.

Record retention belongs in the same conversation. Investigators must keep study records for the periods set in 21 CFR 312.62(c) and 21 CFR 812.140(d), so a contract that leaves your historical data stranded in a system you no longer pay for is a compliance problem, not just an inconvenience.

Evaluation Checklist

• ☐ Sandbox provided with full functionality, not a limited trial tier
• ☐ Two test studies built from your own SOPs (one simple, one complex), with fictional subjects only
• ☐ Screen-failure, unscheduled-visit, and withdrawal scenarios completed
• ☐ Budget built and invoices generated, reconciled by your finance staff
• ☐ Source-documentation workflow tested at the visit level
• ☐ Recruitment, EDC, and health-record integrations verified with test data
• ☐ Vendor validation documentation reviewed, including data transfers and interfaces
• ☐ AI features evaluated only as shipped, not as promised
• ☐ Every finance report on your list produced from the sandbox
• ☐ Workarounds logged and reviewed with the vendor before signing
• ☐ Data-migration and exit terms (your data, in usable form, for the full retention period) in the contract

For the sponsor side of the same question — what sponsors look for when they qualify a site — see our guide to cardiovascular trial site selection criteria, and our sponsor FAQ.

Frequently Asked Questions (FAQ)

How long should a CTMS sandbox evaluation take?

In our experience, two to three weeks of part-time, structured testing is enough for most sites. What matters is coverage: your test studies must exercise your SOPs' hard cases — screen failures, unscheduled visits, invoicing, and reconciliation — not just routine scheduling.

What should a site test first in a new CTMS?

Start where failure costs the most: source documentation at the visit level, and the budget-to-invoice-to-payment chain. FDA inspectors compare source records with case report forms, so source workflow is where weaknesses surface. Scheduling is easy to judge in a demo; source workflow and finance are where systems quietly fail.

Why do sites keep spreadsheets after buying a CTMS?

Usually because the system does not match how the site works. Parallel spreadsheets are a symptom of a skipped evaluation: the gap between the vendor's workflow and the site's SOPs gets filled by staff with the tool they trust. A sandbox trial exposes those gaps before the contract, when they are still the vendor's problem.

What is the biggest hidden cost of switching a CTMS?

Data migration and lost history. Years of study, subject, and financial records must move cleanly, and investigators must keep study records for the periods FDA regulations require. Anything that does not move becomes a blind spot for audits and sponsor reporting. Confirm what migrates — and what your data looks like if you ever leave — before you sign.

Julio G. Martinez-Clark is CEO of Amavita Research Services, a cardiovascular clinical research site in Miami. To talk about a study, contact our sponsor team.

Sources: FDA Compliance Program 7348.811, Clinical Investigators and Sponsor-Investigators (implemented July 22, 2020); 21 CFR 312.62 and 21 CFR 812.140; FDA, Electronic Systems, Electronic Records, and Electronic Signatures in Clinical Investigations: Questions and Answers, guidance for industry (October 2024).